Pranlukast

Drug Profile

Pranlukast

Alternative Names: Azlaire; Dolukast hydrate; ONO 1078; ONO RS 411; Onon; Onon Capsule; Onon Dry Syrup; RS 411; SB 205312; Ultair

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Developer Merck & Co; Ono Pharmaceutical
  • Class Antiallergics; Antiasthmatics; Chromones; Small molecules
  • Mechanism of Action Leukotriene C4 receptor antagonists; Leukotriene D4 receptor antagonists; Leukotriene E4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma
  • Discontinued Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Sinusitis

Most Recent Events

  • 22 Dec 2011 Registered as dry syrup formulation for Allergic rhinitis (in children) in Japan (PO)
  • 30 Apr 2011 Preregistration as dry syrup formulation for Allergic rhinitis (in children) in Japan (PO)
  • 17 Mar 2009 Pharmacokinetics data from a phase I trial in patients with Asthma presented at the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top